Cardinal Health will report its second‐quarter results for fiscal year 2026 on February 5 before the market opens on the New York Stock Exchange. Management will host a webcast at 8:30 a.m. Eastern to discuss performance, strategy updates and guidance implications. The accompanying slide deck will be accessible on the company’s Investor Relations page with no access code required, and both slides and a replay will remain available for 12 months.

In the latest comparative review, Cardinal Health delivered a net margin of 0.68%, reflecting modest profitability on its expansive revenue base. Return on assets stood at 4.19%, signaling efficient utilization of its asset base in pharmaceutical distribution and medical products. Return on equity was reported at –84.37%, driven by a significant, one-time non‐cash charge in the prior period; excluding that adjustment, underlying ROE aligns more closely with peers in the 10–12% range.

For the trailing twelve months, Cardinal Health generated $234.3 billion in gross revenue and net income of $1.56 billion. Adjusted earnings per share totaled $6.63. The company is trading at a price‐to‐sales ratio of 0.21 and a price‐to‐earnings ratio of 31.01, reflecting a premium relative to smaller medical equipment peers but in line with large‐cap distribution platforms.

Cardinal Health’s beta of 0.65 indicates lower volatility compared with the broader S&P 500, underscoring defensive characteristics of its pharmaceutical and medical products distribution model. Institutional investors hold 87.2% of outstanding shares, demonstrating strong confidence from pension funds, endowments and mutual funds. Insider ownership is minimal at 0.1%, consistent with large‐cap healthcare distribution peers.